Published in Healthcare Mergers, Acquisitions and Ventures Week, November 7th, 2009
"Our offer price remains unchanged at $14.50 per share in cash, which is a substantial premium to where Facet Biotech's stock was trading prior to our offer," said Biogen Idec's President and Chief Executive Officer James C. Mullen. "We continue to believe our offer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.